Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2013

Open Access 01-12-2013 | Review

The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality

Authors: David Gustafsson, Robert Unwin

Published in: BMC Nephrology | Issue 1/2013

Login to get access

Abstract

Uric acid is the end product of purine metabolism in humans. High levels are causative in gout and urolithiasis. Hyperuricaemia has also been implicated in the pathophysiology of hypertension, chronic kidney disease (CKD), congestive heart failure (CHF), the metabolic syndrome, type 2 diabetes mellitus (T2DM), and atherosclerosis, with or without cardiovascular events. This article briefly reviews uric acid metabolism and summarizes the current literature on hyperuricaemia in cardiovascular disease and related co-morbidities, and emerging treatment options.
Appendix
Available only for authorised users
Literature
1.
Choi HK, Mount DB, Reginato AM: Pathogenesis of Gout. Ann Intern Med. 2005, 143 (7): 499-516. 10.7326/0003-4819-143-7-200510040-00009.CrossRefPubMed
2.
3.
Choi HK, Curhan G: Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. Br Med J. 2008, 336: 309-312. 10.1136/bmj.39449.819271.BE.CrossRef
4.
Crittenden DB, Pillinger MH: New therapies for gout. Annu Rev Med. 2013, 64: 325-337. 10.1146/annurev-med-080911-105830.CrossRefPubMed
5.
Bobulescu IA, Moe OW: Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis. 2012, 19 (6): 358-371. 10.1053/j.ackd.2012.07.009.CrossRefPubMedPubMedCentral
6.
Hosomi A, Nakanishi T, Fujita T, Tamai I: Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PLoS One. 2012, 7 (2): e30456-10.1371/journal.pone.0030456.CrossRefPubMedPubMedCentral
7.
Dinour D, Bahn A, Ganon L, Ron R, Geifman Holtzman O, Knecht A, Gafter U, Ruth Rachamimov R, Sela BA, Gerhard Burckhardt G, Holtzman EJ: URAT1 mutations cause renal hypouricaemia type 1 in Iraqi Jews. Nephrol Dial Transplant. 2011, 26 (7): 2175-2181. 10.1093/ndt/gfq722.CrossRefPubMed
8.
Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, Mangino M, Albrecht E, Wallace C, Farrall M, Johansson A, Nyholt DR, Aulchenko Y, Beckmann JS, Bergmann S, Bochud M, Brown M, Campbell H, Connell J, Dominiczak A, Homuth G, Lamina C, McCarthy MI, Meitinger T, Mooser V, Munroe P, Nauck M, Peden J, Prokisch H, Salo P, for the EUROSPAN Consortium, et al: Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet. 2009, 5 (6): e1000504-10.1371/journal.pgen.1000504.CrossRefPubMedPubMedCentral
9.
Yang Q, Köttgen A, Dehghan A, Smith AV, Glazer NL, Chen MH, Chasman DI, Aspelund T, Eiriksdottir G, Harris TB, Launer L, Nalls M, Hernandez D, Arking DE, Boerwinkle E, Grove ML, Li M, Kao WHL, Chonchol M, Haritunians T, Li G, Lumley T, Psaty BM, Shlipak M, Hwang SJ, Larsson MG, O'Donnell CJ, Upadhyay A, van Duijn CM, Hofman A, et al: Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet. 2010, 3 (6): 523-530. 10.1161/CIRCGENETICS.109.934455.CrossRefPubMedPubMedCentral
10.
Dinour D, Gray NK, Campbell S, Shu X, Sawyer L, Richardson W, Rechavi G, Amariglio N, Ganon L, Sela BA, Bahat H, Goldman M, Weissgarten J, Millar MR, Wright AF, Holtzman EJ: Homozygous SLC2A9 mutations cause severe renal hypouricemia. J Am Soc Nephrol. 2010, 21 (1): 64-72. 10.1681/ASN.2009040406.CrossRefPubMedPubMedCentral
11.
Köttgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, Pistis G, Ruggiero D, O’Seaghdha CM, Haller T, Yang Q, Tanaka T, Johnson AD, Kutalik Z, Smith AV, Shi J, Struchalin M, Middelberg RPS, Brown MJ, Gaffo AL, Pirastu N, Li G, Hayward C, Zemunik T, Huffman J, Yengo L, Zhao JH, Demirkan A, Feitosa MF, Liu X, et al: Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet. 2013, 45 (2): 145-154.CrossRefPubMed
12.
Moskowitz JL, Piret SE, Lhotta K, Kitzler TM, Tashman AP, Velez E, Thakker RV, Kotanko P: Association between genotype and phenotype in uromodulin-associated kidney disease. Clin J Am Soc Nephrol. in press
13.
Juraschek SP, Kovell LC, Miller ER, Gelber AC: Association of kidney disease with prevalent gout in the United States in 1988–1994 and 2007–2010. Sem Arthritis Rheumatism. 2013, 42 (6): 551-561. 10.1016/j.semarthrit.2012.09.009.CrossRef
14.
Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote´ F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, et al: 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologictherapeutic approaches to hyperuricemia. Arthritis Care Res. 2012, 64 (10): 1431-1446. 10.1002/acr.21772.CrossRef
15.
Yamanaka H: Japanese guideline for the management of hyperuricemia and gout: Second edition. Nucleosides Nucleotides Nucleic Acids. 2011, 30 (12): 1018-1029. 10.1080/15257770.2011.596496.CrossRefPubMed
16.
Schlesinger N: Difficult-to-treat gouty arthritis. A disease warranting better management. Drugs. 2011, 71 (11): 1413-1439. 10.2165/11592290-000000000-00000.CrossRefPubMed
17.
Becker MAH, Ralph Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C: The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010, 12: R63-10.1186/ar2978.CrossRefPubMedPubMedCentral
18.
Ryu HJ, Song R, Kim HW, Kim JH, Lee EY, Lee YJ, Song YW, Lee EB: Clinical risk factors for adverse events in allopurinol users. J Clin Pharmacol. 2013, 53 (2): 211-216. 10.1177/0091270012439715.CrossRefPubMed
19.
Fleischmann R, Shen Z, Yeh L-T, Kerr B, Polvent E, Suster M, Hingorani V, Miner JN, Manhard K, Quart B: Lesinurad (RDEA594), a novel uricosuric agent, in combination with febuxostat shows significant additive urate lowering effects in gout patients with 100% response achieved for all combination dose regimens [abstract]. Ann Rheum Dis. 2011, 70 (Suppl. 3): 188-
20.
Kotz J: The gout pipeline crystallizes. Nature Rev Drug Discov. 2012, 11 (6): 425-426. 10.1038/nrd3748.CrossRef
21.
Ohno I, Yamaguchi Y, Saikawa H, Uetake D, Hikita M, Okabe H, Ichida K, Hosoya T: Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients. Inter Med. 2009, 48 (6): 415-420. 10.2169/internalmedicine.48.1817.CrossRef
22.
Dalbeth N, So A: Hyperuriemia and gout: state of the art and future perspectives. Ann Rheum Dis. 2010, 69 (10): 1738-1743. 10.1136/ard.2010.136218.CrossRefPubMed
23.
24.
Álvarez-Lario B, Macarrón-Vivente J: Is there anything good in uric acid?. QJM. 2011, 104 (12): 1015-1024. 10.1093/qjmed/hcr159.CrossRefPubMed
25.
Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001, 38 (5): 1101-1106. 10.1161/hy1101.092839.CrossRefPubMed
26.
Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ: Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002, 282 (6): F991-F997.CrossRefPubMed
27.
Grayson PC, Kim SY, LaValley M, Choi HK: Hyperuricemia and incident hypertension: A systemic review and meta-analysis. Arthritis Care Res. 2011, 63 (1): 102-110. 10.1002/acr.20344.CrossRef
28.
29.
Feig DI, Soletsky B, Johnson RJ: Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. J Am Med Assoc. 2008, 300 (8): 924-932. 10.1001/jama.300.8.924.CrossRef
30.
Soletsky B, Feig DI: Uric acid reduction rectifies prehypertension in obese adolescents. Hypertens. 2012, 60 (5): 1148-1156. 10.1161/HYPERTENSIONAHA.112.196980.CrossRef
31.
Agarwal V, Hans N, Messerli FH: Effect of allopurinol on blood pressure: A systematic review and meta-analysis. J Clin Hypertens. 2013, 16 (6): 435-442.CrossRef
32.
33.
Choi HK, Soriano LC, Zhang Y, Rodrigues LAG: Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case–control study. Br Med J. 2012, 344: d8190-10.1136/bmj.d8190.CrossRef
34.
Nashar K, Fried LF: Hyperuricemia and the Progression of Chronic Kidney Disease: Is uric acid a marker or an independent risk factor. Adv Chronic Kidney Dis. 2012, 19 (6): 386-391. 10.1053/j.ackd.2012.05.004.CrossRefPubMed
35.
Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ: A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002, 13 (12): 2888-2897. 10.1097/01.ASN.0000034910.58454.FD.CrossRefPubMed
36.
Johnson RJ, Nakagawa T, Jalal D, Sánchez Lozada LG, Kang DH, Ritz E: Uric acid and chronic kidney disease: which is chasing which?. Nephrol Dial Transplant. 2013, in press
37.
Siu YP, Leung KT, Tong MK, Kwan TH: Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006, 47 (1): 51-59. 10.1053/j.ajkd.2005.10.006.CrossRefPubMed
38.
Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J: Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010, 5 (8): 1388-1393. 10.2215/CJN.01580210.CrossRefPubMedPubMedCentral
39.
Momeni A, Shahidi S, Seirafian S, Taheri S, Kheiri S: Effect of allopurinol in decreasing proteinuria in Type 2 diabetic patients. Iranian J Kid Dis. 2010, 4 (2): 128-132.
40.
Shi Y, Chen W, Jalal D, et al: Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res. 2012, 35 (3): 153-160. 10.1159/000331453.CrossRefPubMed
41.
Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, Grobbee DE, Shahinfar S, de Zeeuw D, Lambers Heerspink HJ: Effect of a reduction in uric acid on renal outcomes during losartan treatment: A post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the angiotensin ii antagonist losartan trial. Hypertension. 2011, 58 (1): 2-7. 10.1161/HYPERTENSIONAHA.111.171488.CrossRefPubMed
42.
Krishnan E: Gout and the risk for incident heart failure and systolic dysfunction. Br Med J Open. 2012, 2 (1): e000282-
43.
Tamariz L, Verma S: Uric acid as a predictor of all-cause mortality in heart failure: A Meta-analysis. Congest Heart Fail. 2011, 17 (1): 25-30. 10.1111/j.1751-7133.2011.00200.x.CrossRefPubMed
44.
Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, Goto K, Goto D, Yokota T, Kinugawa S, Yokoshiki H, Takeshita A, Tsutsui H, for the JCARE-CARD Investigators: Hyperuricemia predicts adverse outcome in patients with heart failure. Internat J Cardiol. 2011, 151 (2): 143-147. 10.1016/j.ijcard.2010.05.002.CrossRef
45.
Gotsman I, Kern A, Lotan C, Zwas DR: Changes in uric acid levels and allopurinol use in chronic heart failure: Association with improved survival. J Cardiac Failure. 2012, 18 (9): 694-701. 10.1016/j.cardfail.2012.06.528.CrossRefPubMed
46.
Filippatos GS, Ahmed MI, Gladden JD, Aban IB, Love TE, Sanders PW, Pitt B, Anker SD, Ahmed A: Hyperuricemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Hear J. 2011, 32 (6): 712-720. 10.1093/eurheartj/ehq473.CrossRef
47.
Harzand A, Tamariz L, Hare JM: Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition. Congest Heart Fail. 2012, 18 (3): 179-182. 10.1111/j.1751-7133.2011.00262.x.CrossRefPubMed
48.
George J, Carr E, Davies J, Belch JJF, Struthers A: High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering UA. Circulation. 2006, 114 (23): 2508-2516. 10.1161/CIRCULATIONAHA.106.651117.CrossRefPubMed
49.
Noman A, Ang DSC, Ogston S, Lang CC, Struthers AD: Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010, 375 (9732): 2161-2167. 10.1016/S0140-6736(10)60391-1.CrossRefPubMedPubMedCentral
50.
Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S, Kinugawa T, Igawa O, Hisatome I, Shigemasa C, Anker SD, Doehner W: Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double- blind placebo-controlled crossover preliminary study. Circ Heart Fail. 2010, 3 (1): 73-81. 10.1161/CIRCHEARTFAILURE.109.868604.CrossRefPubMed
51.
Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS: Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?. Metabolism. 2006, 55 (10): 1293-1301. 10.1016/j.metabol.2006.05.013.CrossRefPubMed
52.
Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, Saito A, Sone H: Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009, 32 (9): 1737-1742. 10.2337/dc09-0288.CrossRefPubMedPubMedCentral
53.
Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC: High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care. 2008, 31 (2): 361-362.CrossRefPubMed
54.
Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML: Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003, 42 (3): 474-480.CrossRefPubMed
55.
Kanellis J, Kang DH: Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005, 25 (1): 39.42-CrossRefPubMed
56.
Li C, Hsieh MC, Chang SJ: Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013, 25 (2): 210-216. 10.1097/BOR.0b013e32835d951e.CrossRefPubMed
57.
Facchini F, Chen YD, Hollenbeck CB, Reaven GM: Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. J Am Med Assoc. 1991, 266 (21): 3008-3011. 10.1001/jama.1991.03470210076036.CrossRef
58.
Quinones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciaciaro D, Ferrannini E: Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995, 268 (1): E1-E5.PubMed
59.
Muscelli E, Natali A, Bianchi S, Bigazzi S, Quinones Galvan AQ, Sironi AM, Frascerra S, Ciociaro D, Ferrannini E: Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens. 1996, 9 (8): 746-752. 10.1016/0895-7061(96)00098-2.CrossRefPubMed
60.
Bibert S, Hess SK, Firsov D, Thorens B, Geering K, Horisberger JD, Bonny O: Mouse GLUT9: evidences for a urate uniporter. Am J Physiol Renal Physiol. 2009, 297 (3): F612-619. 10.1152/ajprenal.00139.2009.CrossRefPubMed
61.
Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ, Srivastava S, Kitamura K, Hisatome I, Endou H, Sakurai H: Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem. 2008, 283 (5): 26834-26838.CrossRefPubMed
62.
Price KL, Sautin YY, Long DA, Zhang L, Miyazaki H, Mu W, Endou H, Johnson RJ: Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol. 2006, 17 (7): 1791-1795. 10.1681/ASN.2006030264.CrossRefPubMed
63.
Sautin YY, Nakagawa T, Zharikov S, Johnson RJ: Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol. 2007, 293 (2): C584-596. 10.1152/ajpcell.00600.2006.CrossRefPubMed
64.
Shafiu M, Johnson RJ, Turner ST, Langaee T, Gong Y, Chapman AB, Gums JG, Johnson JA: Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension. Kidney Blood Press Res. 2012, 35 (6): 477-482. 10.1159/000337370.CrossRefPubMedPubMedCentral
65.
Baldwin W, McRae S, Marek G, Wymer D, Pannu V, Baylis C, Johnson RJ, Sautin YY: Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011, 60 (4): 1258-1269. 10.2337/db10-0916.CrossRefPubMedPubMedCentral
66.
Brymora A, Flisinski M, Johnson RJ, Goszka G, Stefanska Manitius J: Low-fructose diet lowers blood pressure and inflammation in patients with chronic kidney disease. Nephrol Dial Transplant. 2012, 27 (2): 608-612. 10.1093/ndt/gfr223.CrossRefPubMed
67.
Mangge H, Zelzer S, Puerstner P, Schnedl WJ, Reeves G, Postolache TT, Weghuber D: Uric acid best predicts metabolically unhealthy obesity with increased cardiovascular risk in youth and adults. Obesity. 2013, 21 (1): E71-E77. 10.1002/oby.20061.CrossRefPubMed
68.
Petta S, Camma CD, Cabibi D, Di Marco V, Craxi A: Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Therapeut. 2011, 24 (7): 757-766.CrossRef
69.
Petta S, Macaluso SF, Cammà C, Di Marco V, Cabibi D, Craxì A: Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. Liver Int. 2012, 32 (9): 1443-1450. 10.1111/j.1478-3231.2012.02842.x.CrossRefPubMed
70.
Bell DSH: Beware of the low urine pH-the major cause of the increased prevalence of nephrolithiasis in the patient with type 2 diabetes. Diabetes Obes Metab. 2012, 14 (4): 299-303. 10.1111/j.1463-1326.2011.01519.x.CrossRefPubMed
71.
Culleton BF, Larson MG, Kannel WB: Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999, 131 (1): 7-13. 10.7326/0003-4819-131-1-199907060-00003.CrossRefPubMed
72.
Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA: Hyperuricemia and coronary heart disease: A systematic review and meta-analysis. Arthritis Rheum. 2010, 62 (2): 170-180.
73.
Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA: Hyperuricemia and risk of stroke: A systematic review and meta-analysis. Arthritis Rheum. 2009, 61 (7): 885-892. 10.1002/art.24612.CrossRefPubMedPubMedCentral
74.
Rablink TJ, Luscher TF: Endothelial nitric oxide synthase: host defense enzyme of the endothelium?. Arterioscler Thromb Vasc Biol. 2006, 26 (2): 267-271.CrossRef
75.
Higgins P, Dawson J, Lees KR, McArthur K, Quinn TJ, Walters MR: Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Therap. 2012, 30 (4): 217-226. 10.1111/j.1755-5922.2011.00277.x.CrossRef
76.
Rajendra NS, Ireland S, George J, Belch JJF, Lang CC, Struthers AD: Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol. 2011, 58 (8): 820-828. 10.1016/j.jacc.2010.12.052.CrossRefPubMed
77.
Dogan A, Yarlioglues M, Kaya MG, Karadag Z, Dogan S, Ardic I, Dogdu O, Kilinc Y, Zencir C, Akpek M, Ozdogru I, Oguzhan Kalay AN: Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Press. 2011, 20 (3): 182-187. 10.3109/08037051.2010.538977.CrossRefPubMed
78.
Greig D, Alcaino H, Castro PF, Garcia L, Verdejo HE, Navarro M, López R, Mellado R, Tapia F, Gabrielli LA, Nogerol C, Chiong M, Godoy I, Lavandero S: Xanthine-oxidase inhibitors and statins in chronic heart failure: Effects on vascular and functional parameters. J Heart Lung Transpl. 2011, 30 (4): 408-413. 10.1016/j.healun.2010.10.003.CrossRef
79.
Waring WS, McKnight JA, Webb DJ: Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. Diabetologia. 2007, 50 (12): 2572-2579. 10.1007/s00125-007-0817-7.CrossRefPubMed
Metadata
Title
The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality
Authors
David Gustafsson
Robert Unwin
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2013
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-14-164

Other articles of this Issue 1/2013

BMC Nephrology 1/2013 Go to the issue

Research article

Haplotype association analysis of genes within the WNT signalling pathways in diabetic nephropathy

Research article

Fibroblast growth factor 23 is associated with carotid artery calcification in chronic kidney disease patients not undergoing dialysis: a cross-sectional study

Research article

Combined effect of mitochondrial DNA 5178 C/A polymorphism and alcohol consumption on estimated glomerular filtration rate in male Japanese health check-up examinees: a cross-sectional study

Research article

Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs)

Research article

Chronic kidney disease is associated with adverse outcomes among elderly patients taking clopidogrel after hospitalization for acute coronary syndrome

Research article

Vascular calcification on plain radiographs is associated with carotid intima media thickness, malnutrition and cardiovascular events in dialysis patients: a prospective observational study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits